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ing of perspectives and rationales for decisions. Intended to measure value in its 
broad sense, the framework supports sustained application of MCDA in health care 
decisionmaking.
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Objectives: To identify the types of coverage recommendations made by key 
ex-US health technology assessment (HTA) organizations for biologic treatments 
in Crohn’s disease (CD) and to understand how these organizations interpret evi-
dence to support these recommendations. MethOds: Publicly available HTAs on 
CD from January 2009 to June 2013 for the following organizations were reviewed: 
CADTH (Canada), CONITEC (Brazil), HAS (France), IQWiG (Germany), NICE (UK), PBAC 
(Australia), and ISCIII (Spain). HTAs were identified using an HTA search engine 
and were supplemented with separate manual searches for CD-related reports on 
each HTA organization’s website. When additional context was needed to evaluate 
the HTA with the most recent recommendations, older HTAs were identified and 
reviewed. For each organization, the recommendation and corresponding clinical 
and economic rationales were reviewed and extracted. Results: In total, nine HTAs 
were reviewed across five organizations; no HTAs on CD from IQWiG or ISCIII were 
identified. All HTAs endorsed the use of infliximab and adalimumab for CD from a 
clinical perspective. Recommendations for subpopulations including fistulizing dis-
ease, pediatrics, and prior/concurrent corticosteroid use varied. Recommendations 
were consistent with the host country’s approved labeled indications when appro-
priate cost thresholds were met, with the exception of PBAC, where adalimumab was 
additionally deemed appropriate for fistulizing disease, and CONITEC, where certoli-
zumab was not endorsed due to safety concerns. Research gaps identified include 
the lack of head-to-head trials for adalimumab vs. infliximab and the paucity of 
long-term clinical and economic evidence. cOnclusiOns: Infliximab and adali-
mumab generally received positive endorsements in CD, despite being frequently 
scrutinized by HTA organizations for their high costs. The expiration of patents and 
the introduction of biosimilars will likely shift how HTA entities evaluate clinical, 
economic, and humanistic evidence for biologic treatments for CD in the future.
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Objectives: The purpose of this study was to identify factors leading to unfa-
vourable reviews of cost-effectiveness analyses (CEAs) for oncology products by 
comparing recent summary reports from multiple HTA agencies. MethOds: We 
utilised reports issued by HTA agencies of the UK (NICE), Scotland (SMC), Canada 
(pCODR), and Australia (PBAC) for this study due to their detailed and publicly avail-
able evaluations of CEA submissions. We examined the factors driving unfavourable 
appraisals by comparing recent reports of 13 selected oncology drugs launched 
between January 2012 and December 2013. The following factors were examined and 
compared as predictors for negative decisions: (1) nature of the modelled patient 
population, (2) comparator selection, (3) survival analysis approach, and (4) sensi-
tivity analyses performed. Results: Issues related to one or more of these factors 
were often cited as leading to higher and more uncertain ICER values that HTA 
bodies viewed unfavourably. The SMC and NICE frequently took issue whether the 
patient populations sourced as inputs into the CEAs were representative of the 
intended indication in each respective country. All HTA agencies took issue with 
survival analysis methods that assumed a carry-over of benefit into post-treatment 
states. Similarly, HTA bodies typically critically examined the extrapolation meth-
odology of studies with immature survival data. Although various combinations 
of these identified factors were likely to lead to negative HTA decisions, robust 
sensitivity analyses (especially regarding extrapolation methods and input sources) 
that clearly identified the factors driving ICER values were cited favourably by HTA 
agencies. cOnclusiOns: Manufacturers must carefully select the survival analy-
sis approach that is suitable for their asset given the clinical data available, such 
that the benefit of their product is not overstated; performing robust sensitivity 
analyses to account for uncertainty may help to maximise favourable HTA appraisal 
outcomes in CEA markets.
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Objectives: Non-adherence rates with oral endocrine therapy (ET) in women 
with breast cancer (BC) are 25%-50% and lead to inferior survival. Understanding 
the effect of non-adherence on health outcomes is necessary to develop effec-
tive interventions. This study examined real-world non-adherence and health 
outcomes among women using ET. MethOds: Female respondents from the 
2010-2012 U.S. National Health and Wellness Survey were included if reporting a 
diagnosis of BC and treatment with aromatase inhibitors (n= 261), selective estrogen 
receptor modulators (n= 113), or their combination (n= 7). The Morisky Medication 
Adherence Scale (MMAS-4 or MMAS-8, modified for use in oncology) was used to 
assess adherence, standardized using z-scores. Descriptive analyses examined 
adherence, sociodemographics, and health behaviors. Bivariate analyses com-
formulary listing recommendations to publicly funded drug plans. This study aims 
to determine the implications of implementing CDR recommendations. MethOds: 
CDR reviews from December 2010 to December 2012, for which an economic evalu-
ation was submitted by the manufacturer, were assessed. A framework was devel-
oped where templates were created in Microsoft Excel for each drug submission to 
consider two scenarios: an uptake scenario (CDR recommendation implemented), 
and a counterfactual scenario (CDR recommendation not implemented). Drug costs 
and quality adjusted life years (if applicable) for both scenarios were determined at 
the population level using patient numbers reported in the manufacturer’s budget 
impact analyses. The incremental net benefit was calculated, based on a willing-
ness-to-pay of $50,000. In addition, sensitivity analyses were conducted to consider 
variation around the counterfactual scenario. Results: Based on the results for the 
55 drugs for which cost-utility or a cost-minimization analysis was submitted, the 
total incremental net benefit of implementing a CDR recommendation was calcu-
lated to be over 1 billion dollars over a 1-year time frame for participating provincial 
drug plans. Detailed sensitivity analysis explored the uncertainty around these 
estimates. cOnclusiOns: Overall, the 10 drug plans included for this analysis 
would realize significant benefit by implementing CDR recommendations. Based 
on this research, a framework to assess the impact of CDR recommendations is 
being developed. Next steps include, consideration of disease specific estimates 
of net benefit and the inclusion of all participating drug plans to provide broader 
implications of overall CDR impact in Canada.
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Objectives: Due to a substantial oncology burden across the globe, there is an 
increasing need for innovative, more effective oncology treatments. Although the 
decision-making process differs among nations, health technology assessments 
(HTAs) aim to produce policies that achieve optimal value while improving patient 
care and health outcomes. The objective of this analysis was to evaluate recent 
patterns in oncology-based HTA decisions in selected countries. MethOds: HTA 
surveillance was conducted for Australia, Canada, France, Germany, and the United 
Kingdom (UK) from January 1, 2012 to August 31, 2013 (19 months). Oncology-based 
HTAs were evaluated by therapeutic area, decision, and rationale for the decision. 
Decisions were categorized as favorable, unfavorable, mixed (ie, both favorable 
and unfavorable), and neutral (ie, deferral). Results: 67 oncology-related HTAs 
were published in the study timeframe. Across studied nations, 38 (57%) decisions 
were favorable, 25 (37%) unfavorable, 1 (1%) mixed, and 3 (4%) neutral. Of those 
unfavorable decisions, 13 were rejected for insufficient benefit to justify the high 
cost (ie, improperly high incremental cost-effectiveness ratio [ICER]), 9 for insuf-
ficient or unproven clinical benefit vs the most appropriate comparator, and 3 for 
incomplete or improper submission. Excluding mixed and neutral decisions, France 
was associated with the highest percentage of favorable decisions (14 of 15; 93%), 
followed by Germany (9 of 14; 64%), Australia (11 of 20; 55%), and the UK (4 of 14; 
29%). cOnclusiOns: Based on the last 19 months of oncology-based HTAs, over 
50% of decisions were favorable. The most significant factor leading to rejection for 
oncology products is the inability to prove cost-effectiveness vs the most appropri-
ate comparator, followed by unproven clinical benefit. This analysis suggests that 
manufacturers would have more success with HTA decisions, particularly in the UK, 
if more robust health economic and clinical data are generated.
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bAckgROund: Appraising rare disease treatments involves multiple issues and 
represents a significant challenge for HTA agencies. Multicriteria-approaches are 
uniquely suited to assess their real life value. Objectives: were to develop a frame-
work adapted to rare diseases while remaining compatible with other therapeutic 
areas for broad application. MethOds: Adaptation of the framework to rare dis-
eases was based on methodological and ethical principles underlying the EVIDEM 
framework, informed by issues and policies specific to rare diseases, which were 
identified through literature review and survey, and guided by pragmatic considera-
tions of real life application in participatory processesCriteria selection followed 
MCDA principles: completeness; non-redundancy; operationalizability; and inde-
pendence. MCDA model mechanics and sensitivity analyses were designed based 
on a review of MCDA modeling. Results: Quantitative criteria of the framework are 
organized into a hierarchical MCDA model consisting of six domains of value (top-
level criteria): Need, Type of benefit, Outcomes, Economic consequences, Knowledge, and 
Established priorities. Each domain includes criteria and subcriteria, each contributing 
to the final output of the model, i.e., the Value Estimate. The model explicitly takes 
into account aspects of rare diseases, including: disease complexity; treatment 
outcomes complexity; multiple economic and social consequences; data limita-
tions and innovative approaches to tackle these; and health care system priorities. 
Weighting and scoring methodologies capture individual perspectives and judg-
ments on the meaning of data while allowing for full exploration of uncertainty 
through six types of sensitivity analyses. Qualitative criteria support consideration 
of the impact of contextual issues. cOnclusiOns: This framework promotes a 
comprehensive, transparent and systematic appraisal of rare disease treatments 
while remaining applicable to any therapy. Although numerical outputs are pro-
duced, the framework is intended to support deliberative processes that allow shar-
